¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"minimal effective dose"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
¿µ¹® radiation dose ÇÑ±Û ¹æ»ç¼±·®
¼³¸í   
  ¹æ»ç¼±Á¶»çÀÇ Á¤µµ. ¹æ»ç¼±»ý¹°ÇÐÀ̳ª ÀÎüÀÇ ¹æ»ç¼±¹æÈ£¿¡¼­´Â Àü¸®¹æ»ç¼±ÀÇ ¾ç, Áï ¼±·®ÀÌ ¹®Á¦°¡ µÈ´Ù. ¹æ»ç¼±·®¿¡¼­µµ ±¹Á¦´ÜÀ§°è(SI)°¡ Ã¤¿ëµÇ¾î ±¹Á¦¹æ»ç¼±¹æÈ£À§¿øÈ¸(ICRP)ÀÇ ±Ç°í¿¡ µû¶ó¼­ ´ÙÀ½ÀÇ ¿©·¯ ´ÜÀ§°¡ ³Î¸® »ç¿ëµÈ´Ù. ¨ç Èí¼ö¼±·®(absorbed dose). ¹°ÁúÀÇ ´ÜÀ§Áú·®ÀÌ ¹æ»ç¼±¿¡ ÀÇÇØ ¹Þ¾ÆµéÀ̴ ¿¡³ÊÁö. ÀÌ ´ÜÀ§´Â ¹æ»ç¼± ¹× ¹°ÁúÀÇ Á¾·ù°¡ ¾î¶°ÇÑ °ÍÀÌ´õ¶óµµ »ç¿ëÇÒ ¼ö ÀÖ´Ù. ±¹Á¦´ÜÀ§´Â J/kgÀ̸ç À̰Ϳ¡ °íÀ¯ÇÑ ¸íĪÀ¸·Î ±×·¹ÀÌ(gray, ±âÈ£ Gy)°¡ ºÎ¿©µÈ´Ù. 1Gy=100¶óµå(rad). ¨è Á¶»ç¼±·®(exposure) ¶Ç´Â °øÁß¼±·®. X¼± ¶Ç´Â ¥ã¼±¿¡ ÇÑÇØ¼­ »ç¿ëµÈ´Ù. ±¹Á¦´ÜÀ§´Â C/kg. ¨é ¼±·®´ç·®(dose equivalent). ¹æ»ç¼±¹æÈ£¸¦ À§ÇØ »ç¿ëµÇ´Â ¾ç. ±âÈ£´Â H. H´Â ¹æ»ç¼±ÀÇ Á¾·ù¿Í ¿¡³ÊÁö¿¡ ÀÇÇØ »ýü¿¡ Áִ ȿ°ú¸¦ º¸Á¤Çϴ ¼±Áú°è¼ö(Q)¿Í ±× ¹ÛÀÇ ÀÎÀÚ(¿¹¸¦ µé¸é ¼±·®·ü, ¹æ»ç¼ºµ¿À§¿ø¼Ò¿¡ ÀÇÇÑ ³»ºÎÇÇÆø½Ã¿¡´Â ±× ÇÙÁ¾ÀǠü³»ºÐÆ÷ µî)¿¡ ±Ù°ÅÇÑ º¸Á¤°è¼ö(N)¸¦ Èí¼ö¼±·®(D)¿¡ °öÇÑ °Í, Áï H=D-Q-N. ¶ÇÇÑ DÀÇ ´ÜÀ§¸¦ Gy ¶Ç´Â rad·Î Ç¥½ÃÇÏ¿´À» ¶§ HÀÇ ´ÜÀ§¸¦ °¢°¢ ½Ãº£¸£Æ®(sievert, ±âÈ£ Sv) ¹× ·½(rem)À̶ó°í ÇÑ´Ù. µû¶ó¼­ 1 Sv=102rem. ÀϹÝÀûÀ¸·Î ´ÜÀ§½Ã°£´çÀÇ ¼±·®À» ¼±·®·ü(dose rate)À̶ó°í ÇÑ´Ù.
¿µ¹® dose ÇÑ±Û ¿ë·®, Åõ¿©·®, ¹æ»ç¼±·®
¼³¸í   
  1. ¾àÁ¦¸¦ ÇÑ ¹ø ¶Ç´Â ÇÏ·ç¿¡ »ç¿ëÇϰųª º¹¿ëÇϴ ºÐ·®. 2. ¹°ÁúÀ̳ª Á¶Á÷¿¡ ´ëÇÑ ¹æ»ç¼±ÀÇ ÀÛ¿ë Á¤µµ¸¦ ³ªÅ¸³»´Â ¾ç. Áï, ¹æ»ç¼±·®À̶ó´Â °³³äÀº ¾î¶² ÇÑ Á¡¿¡ ÀÔ»çÇϴ ¹æ»ç¼±°ú ±× Á¡ ±Ùó¿¡ Àִ ¹°Áú¿¡ ´ëÇÑ ¹æ»ç¼±ÀÇ ¹°¸®Àû-È­ÇÐÀû-»ý¹°ÇÐÀû È¿°ú¿ÍÀÇ °ü°Ô¸¦ Á¤·®ÀûÀ¸·Î ³ªÅ¸³»´Â °øÅëÀΠôµµ·Î¼­ »ý°¢µÈ °ÍÀÌ´Ù. ¶óµå(rad)·Î ³ªÅ¸³»´Â Èí¼ö·®, ·»Æ®°Õ(R)À¸·Î ³ªÅ¸³»´Â Á¶»ç ¼±·®, ·½(rem)À¸·Î ³ªÅ¸³»´Â ¼±·® ´ç·®À¸·Î ±¸ºÐÇÏ¿© ¾´´Ù.
¿µ¹® skin dose ÇÑ±Û ÇǺμ±·®
¼³¸í   
  1. ÇǺÎÇ¥¸é¿¡¼­ÀÇ ¹æ»ç¼±ÀÇ °øÁß¼±·®À¸·Î ¿©±â¿¡´Â 1Â÷¹æ»ç¼±°ú ÈĹæ»ê¶õÀÌ Æ÷ÇԵȴÙ. 2. ÇǺο¡ Èí¼öµÇ´Â ¼±·®.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • minimal effective dose
    ÃÖ¼ÒÀ¯È¿·®
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • minimal effective analgesic concentration
    ÃÖ¼ÒÈ¿°úÁøÅë³óµµ
  • minimal erythema dose
    ÃÖ¼ÒÈ«¹Ý¼±·®
  • minimal infecting dose
    ÃÖ¼Ò°¨¿°¿ë·®
  • minimal lethal dose
    1. ÃÖ¼ÒÄ¡»ç·® 2. ÃÖ¼ÒÄ¡»ç¼±·®
  • biologically effective dose
    »ý¹°ÇÐÀûÀ¯È¿¼±·®
  • collective effective dose
    Áý´ÜÀ¯È¿¼±·®
  • committed effective dose
    ¿¹Å¹À¯È¿¼±·®
  • effective dose
    1. À¯È¿¿ë·® 2. À¯È¿¼±·®
  • effective dose equivalent
    À¯È¿¼±·®ÇØ´ç·®
  • individual effective dose
    °³ÀÎÀ¯È¿¿ë·®
  • mean effective dose
    Æò±ÕÀ¯È¿¼±·®
  • median effective dose
    1. Áß°£À¯È¿¿ë·® 2. Áß°£À¯È¿¼±·®
  • minimal
    ÃÖ¼Ò-
  • minimal alveolar concentration
    ÃÖ¼ÒÆóÆ÷³óµµ
  • minimal anesthetic concentration
    ÃÖ¼Ò¸¶Ãë³óµµ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • effective dose
    À¯È¿¿ë·®, À¯È¿¼±·®
  • minimal invasive surgery
    ÃÖ¼Òħ½À¼ö¼ú
  • effective demand
    À¯È¿¼ö¿ä
  • effective blood volume
    À¯È¿Ç÷¾×·®
  • dose
    ¿ë·®, Åõ¿©·®, ¹æ»ç¼±·®
  • average dose
    Æò±Õ¿ë·®, Æò±Õ¼±·®
  • booster dose
    Ãß°¡Á¢Á¾·®, Ãß°¡¿ë·®
  • lethal dose
    Ä¡»ç·®
  • maximum dose
    ÃÖ´ë¿ë·®, ÃÖ´ë¼±·®
  • optimum dose
    ÀûÁ¤¿ë·®, ÀûÁ¤¼±·®
  • radiation dose
    ¹æ»ç¼±·®
  • radiation absorbed dose
    Èí¼ö¼±·®
  • skin dose
    ÇǺμ±·®
  • therapeutic dose
    Ä¡·á¿ë·®, Ä¡·á¼±·®
  • high-dose
    °í¿ë·®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • minimal effective dose
    ÃÖ¼ÒÀ¯È¿·®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • minimal effective analgesic concentration
    ÃÖ¼ÒÈ¿°úÁøÅë³óµµ
  • minimal erytherma dose
    ÃÖ¼ÒÈ«¹Ý¼±·®
  • minimal lethal dose
    ÃÖ¼ÒÄ¡»ç·®, ÃÖ¼ÒÄ¡»ç¼±·®
  • biologically effective dose
    »ý¹°ÇÐÀûÀ¯È¿¼±·®
  • collective effective dose
    Áý´ÜÀ¯È¿¼±·®
  • committed effective dose
    ¿¹Å¹À¯È¿¼±·®
  • effective dose
    À¯È¿¿ë·®, À¯È¿¼±·®
  • individual effective dose
    °³ÀÎÀ¯È¿¿ë·®
  • mean effective dose
    Æò±ÕÀ¯È¿¼±·®
  • median effective dose
    Áß°£À¯È¿·®, Áß°£À¯È¿¼±·®
  • effective dose equivalent
    À¯È¿¼±·®ÇØ´ç·®
  • minimal visible angle
    Ãּҽð¢
  • minimal alveolar concentration
    ÃÖ¼ÒÆóÆ÷³»³óµµ
  • minimal anesthetic concentration
    ÃÖ¼Ò¸¶Ãë³óµµ
  • minimal bactericidal concentration
    ÃÖ¼Ò»ì±Õ³óµµ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Kobraks minimal stimulation
    ÄÚºê¶ô¾àÀڱعý
  • ED 50=£¾effective dose 50%
    50% À¯È¿·®, Áß°£À¯È¿·®.
  • ED 50=£¾effective dose 50%
    50% À¯È¿·®.
  • MED => minimum effective dose
    ÃÖ¼ÒÈ«¹Ý·®
  • MED=> minimum effective dose
    ÃÖ¼ÒÀ¯È¿·®.
  • MED=£¾minimum effective dose
    ÃÖ¼ÒÀ¯È¿·®.
  • EAV=£¾effective alveolar ventilation
    À¯È¿ÆóÆ÷ȯ±â(·®).
  • ELBF=£¾effective liver blood flow
    À¯È¿¼º °£Ç÷·ù.
  • ELBF=£¾effective liver blood flow
    À¯È¿ °£Ç÷·ù.
  • EPNDB =effective perceived noise level
    ½ÇÈ¿°¨¼ö¼ÒÀ½·¹º§, ½ÇÁ¦°¨°¢¼ÒÀ½
  • ERPF => effective renal plasma flow
    À¯È¿½ÅÇ÷ÀåÀ¯Åë·®
  • ERPF=£¾effective renal plasma flow
    À¯È¿½ÅÇ÷·ù·®.
  • ED 50=ÊÝeffective dose 50%
    50% À¯È¿·®.
  • ED=ÊÝeffective dose
    À¯È¿·®.
  • ID50 (50% infectious dose)
    50% °¨¿°·®
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • minimal effective dose
    ÃÖ¼ÒÀ¯È¿·®.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • minimal effective analgesic concentration
    ÃÖ¼ÒÈ¿°úÀûÁøÅë³óµµ
  • minimal dose =minimum d.
    ÃÖ¼Ò·®(õÌá³åÖ).
  • minimal erythema dose
    ÃÖ¼ÒÈ«¹Ý·®(¡­ûõÚèåÖ).
  • minimal erythema dose
    ÃÖ¼ÒÈ«¹Ý·®(¡­ûõÚèåÖ)
  • minimal infecting dose
    ÃÖ¼Ò°¨¿°·®(õÌá³ÊïæøåÖ).
  • minimal lethal dose
    ÃÖ¼ÒÄ¡»ç·®(õÌá´öÈÞÝåÖ).
  • minimal lethal dose
    ÃÖ¼ÒÄ¡»ç·®(̧ËÛ̬Ë×Ëâ).
  • minimal lethal dose
    ÃÖ¼ÒÄ¡»ç·®(õÌá³öÈÞÝåÖ).
  • minimal phototoxicity dose
    ÃÖ¼Ò±¤µ¶·®
  • biologically effective dose
    »ý¹°ÇÐÀûÀ¯È¿¼±·®
  • collective effective dose
    Áý´ÜÀ¯È¿¼±·®
  • committed effective dose
    ¿¹Å¹À¯È¿¼±·®
  • committed effective dose equivalent
    ¿¹Å¹À¯È¿¼±·®´ç·®
  • effective dose
    À¯È¿¼±·®
  • effective dose 50%
    50% À¯È¿·®, Áß°£À¯È¿·®.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • median effective dose
    Á¤Áß À¯È¿·®(ïáñéêóüùÕá)
  • minimal medium
    ÃÖ¼Ò¹èÁö(õÌá³ÛÆò¢)
  • minimal stable length
    ÃÖ¼Ò¾ÈÁ¤(õÌá³äÌïÒ) ±æÀÌ
  • effective concentration
    À¯È¿ ³óµµ (êóüùÒØÓø)
  • effective half-life
    À¯È¿ ¹Ý°¨±â(êóüùÚâÊõÑ¢)
  • effective lethal phase
    À¯È¿ Ä¡»ç±â(êóüùöÈÞÝÑ¢)
  • absorbed dose
    Èí¼ö·® (ýåâ¥Õá)
  • air dose
    ´ë±â¼±·®(ÓÞѨàÊÕá)
  • booster dose
    ºÎ½ºÅÍ ·®(Õá)
  • dose-response curve
    ¿ë·®´ëÀÀ °î¼±(é»ÕáÓßëëÍØàÊ)
  • exposure dose
    ³ëÃâ·®(ÖÚõóÕá)
  • fractionated dose
    ºÐÇÒ·®(ÝÂùÜÕá)
  • half-value dose
    ¹Ý(Úâ)°ª ¼±·®(àÊÕá)
  • lethal dose
    Ä¡»ç·®(öÈÞÝÕá)
  • maximum permissible dose
    ÃÖ´ëÇã¿ë·®(õÌÓÞúÉé»Õá)
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • minimal effective dose
    ÃÖ¼ÒÀ¯È¿·®
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • effective half life
    À¯È¿¹Ý°¨±â
  • effective TR
    À¯È¿¹Ýº¹½Ã°£
  • minimal
    ÃÖ¼ÒÀÇ
  • minimal enhancement
    ¹Ì¹ÌÇÑÁ¶¿µÁõ°­, °æµµÀÇÁ¶¿µÁõ°­
  • air dose
    °øÁß¼±·®, °ø±âÁß¼±·®
  • cumulative dose
    ÁýÀû¼±·®, ´©ÀûÁ¶»ç·®, ´©Àû¿ë·®, Ãàô¿ë·®
  • curative dose
    ġȿ·®
  • depth dose
    ½ÉºÎ¼±·®
  • dose rate
    ¼±·®·ü
  • fatal dose
    Ä¡»ç·®
  • half lethal dose
    ¹ÝÄ¡»ç·®
  • LD = lethal dose
    Ä¡»ç·®
  • lethal dose [=LD]
    Ä¡»ç·®
  • maintenance dose
    À¯Áö¿ë·®
  • maximal acceptable dose
    ÃÖ´ëÇã¿ë¼±·®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
MRD maximum rate of depolarization; measles-rindenpest-distemper [virus group]; medical records departme...
ID identification; iditol dehydrogenase; immunodeficiency; immunodiffusion; immunoglobulin deficiency; ...
MPD main pancreatic duct; maximum permissible dose; mean population doubling; membrane potential differe...
TD tabes dorsalis; tardive dyskinesia; T-cell dependent; temporary disability; terminal device; tetanus...
MLD manual lymph drainage; median lethal dose; metachromatic leukodystrophy; minimal lesion disease; min...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
MED Minimal effective dose
M.E.C. minimal effective concentration
BED Biologically Effective Dose
ED50 Effective Dose
ED50 Effective Dose 50
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • minimal dose
    ÃÖ¼Ò·®
  • committed effective dose equivalent
    ¿¹Å¹ À¯È¿ ¼±·® ´ç·®
  • effective dose 50%
    Áß°£ À¯È¿·®, 50% À¯È¿·®
    µ¿¹°¿¡ µ¶¼Ò³ª ¾à¹° Åõ¿© ½Ã, 50%ÀÇ µ¿¹°¿¡¼­ À¯È¿ÇÏ´Ù°í ÃßÁ¤µÇ´Â ¿ë·®.
  • mean effective dose
    50% À¯È¿·®
  • Eagle`s minimal essential medium
    ÀÌ±Û ¹èÁö
    ¼¼Æ÷ ¹è¾ç¾×ÀÇ ÀÏÁ¾. 3Á¾·ùÀÇ ¾Æ¹Ì³ë»ê°ú 8Á¾·ùÀÇ ºñŸ¹ÎÀ» ÇÔÀ¯Çϰí ÀÖÀ¸¸ç º¸Åë Ç÷û 5% ÀÌÇÏ¿¡¼­ À¯Áö ¹èÁö·Î¼­ »ç¿ëµÇ°í 10-20%ÀÇ Ç÷û ÷°¡·Î ¸¹Àº ¼¼Æ÷´Â ±ØÈ÷ ¾çÈ£ÇÑ ¹ßÀ°À» ³ªÅ¸³½´Ù.
  • minimal
    ÃÖ¼ÒÀÇ
    °¡Àå °¡´É¼ºÀÌ ÀûÀº.
  • minimal enhancement
    ¹Ì¹ÌÇÑ Á¶¿µ Áõ°­, °æµµÀÇ Á¶¿µ Áõ°­
  • minimal identifiable odor
    ÃÖ¼Ò ºÐÇØ Ãë°¢
  • minimal requirement
    ÃÖ¼Ò ±Ô°Ý
  • minimal temperature
    ÃÖÀú ¿Âµµ
  • effective
    À¯È¿ÇÑ
    ÀǵµµÈ °á°ú¸¦ ÀÏÀ¸Å³ ¼ö ÀÖ´Â.
  • effective arterial volume
    À¯È¿ µ¿¸ÆÇ÷·®
  • effective blood volume
    À¯È¿ Ç÷¾×·®
  • effective diameter
    À¯È¿ Áö¸§
  • effective focal spot
    ½ÇÈ¿ ÃÊÁ¡
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
median effective dose The dose that produces the desired effect; when followed by a subscript (generally "ED50"), it denotes the dose having such an effect on a certain percentage (e.g., 50%) of the test animals; ED50 is the median effective dose, in radiation protection, the sum of the equivalent doses in all tissues and organs of the body weighted for tissue effects of radiation. The unit of effective dose is the sievert (Sv), epilation dose, the minimum amount of radiation sufficient to produce hair loss, usually in 10 to 14 days.
(05 Mar 2000)
minimal dose <pharmacology> The smallest amount of a drug or physical procedure that will produce a desired physiologic effect in an adult.
(05 Mar 2000)
minimal infecting dose <microbiology> The smallest quantity of infectious material regularly producing infection; usually expressed as I.D.50, the quantity causing infection in 50% of a suitable series of animals or cells (cell cultures).
(05 Mar 2000)
minimal lethal dose <pharmacology> The minimal dose of a toxic substance or infectious agent that is lethal, as assayed in various experimental animals (e.g., the least amount of diphtheria toxin that, on an average, kills a 250-g guinea pig within 96 hours after subcutaneous inoculation).
When followed by a subscript (generally "MLD50"), denotes the minimal dose that is lethal to a certain percentage (e.g., 50%) of animals so assayed, LD05.
See: lethal dose.
(05 Mar 2000)
minimal reacting dose The minimal dose of a toxic substance causing a reaction, as manifested in the skin of a series of susceptible test animals; the assay is based on the development of a characteristic, minimal but definite, "standard," focal inflammation (congestion and oedema, induration, degenerative changes, and desquamation of epidermal cells).
(05 Mar 2000)
effective dose The dose that produces the desired effect; when followed by a subscript (generally "ED50"), it denotes the dose having such an effect on a certain percentage (e.g., 50%) of the test animals; ED50 is the median effective dose, in radiation protection, the sum of the equivalent doses in all tissues and organs of the body weighted for tissue effects of radiation. The unit of effective dose is the sievert (Sv), epilation dose, the minimum amount of radiation sufficient to produce hair loss, usually in 10 to 14 days.
(05 Mar 2000)
aperture, effective <microscopy> The diameter of the entrance pupil: it is the apparent diameter of the limiting aperture measured from the front.
(05 Aug 1998)
renal blood flow, effective The amount of blood flowing to the parts of the kidney that are involved with the production of constituents of urine. It is that portion of the total renal blood flow that perfuses functional renal tissue (e.g., the glomeruli). It should be differentiated from renal plasma flow, effective which is based on the amount of plasma rather than on total renal blood.
(12 Dec 1998)
minimal Smallest or least, the smallest possible.
Origin: L. Minimus = least
(18 Nov 1997)
minimal air The volume of gas that remains in the lungs and cannot be expelled after they have been removed from the body, or after the chest has been opened.
(05 Mar 2000)
minimal alveolar concentration The end-alveolar concentration of an inhalation anaesthetic which prevents somatic response to a painful stimulus in 50% of individuals; an index of relative potency of inhalation anaesthetics.
Synonym: minimal anaesthetic concentration.
(05 Mar 2000)
minimal amplitude nystagmus Nystagmus of so small an amplitude that it is not detected by the usual clinical tests.
Synonym: minimal amplitude nystagmus.
Origin: micro-+ G. Nystagmos, a nodding
(05 Mar 2000)
minimal anaesthetic concentration The end-alveolar concentration of an inhalation anaesthetic which prevents somatic response to a painful stimulus in 50% of individuals; an index of relative potency of inhalation anaesthetics.
Synonym: minimal anaesthetic concentration.
(05 Mar 2000)
minimal brain dysfunction An inability to control behaviour due to difficulty in processing neural stimuli.
(12 Dec 1998)
minimal-change disease <nephrology> A disorder of the kidneys which largely affects the glomerulus, the blood filtering structure.
This disorder is one common cause of nephrotic syndrome, minimal glomerular changes, in children affecting 2 to 3 children per 100,000 population under age 16 in the USA. Minimal change disease is also seen rarely in adults. The cause is unknown but may be related to an autoimmune illness.
It is marked by oedema, albuminuria, and an increase in cholesterol in the blood, but otherwise with fairly good renal function. Tubular epithelium is vacuolated by cholesterol droplets, but the glomeruli show only that the foot processes of the glomerular epithelial cells are fused, probably secondary to the proteinuria; the cause of the increased glomerular permeability to plasma protein is unknown.
Risk factors include a history for a immune disorder, recent immunisation or a bee sting.
Diagnosis is made by renal biopsy.
Treatment include systemic corticosteroids which are usually quite effective in curing this disease. Other medications include chlorambucil and cyclophosphamide. In most cases, a moderate protein diet (1 gram protein per Kg body weight per day) will be recommended. Salt (sodium) restriction can be helpful to reduce swelling and vitamin D is usually supplemented.
Synonym: lipoid nephrosis
(27 Sep 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • dose
    ¾àÀÇ 1ȸºÐ;~¿¡ Åõ¾àÇÏ´Ù;º¹¿ë½ÃŰ´Ù
  • maximum dose
    (¾àÀÇ) ±Ø·®
  • minimum dose
    ÃÖ¼Ò Åõ¾à·®
  • minimal
    ±Ø¼ÒÀÇ; ÃÖÀúÀÇ
  • minimal
    ÃÖ¼ÒÇâ(¼ö)ÀÇ;±Ø¼ÒÀÇ
  • minimal art
    ¹Ì´Ï¸Ö ¾ÆÆ®;ÃÖ¼ÒÇÑÀÇ Á¶Çü ¼ö´ÜÀ¸·Î Á¦ÀÛµÈ ±×¸²;Á¶°¢
  • minimal brain dysfunction
    ¹Ì¼Ò ³ú±â´É Àå¾Ö (¾Æµ¿ÀÇ ÇнÀ Àå¾ÖÀÇ Çϳª)
  • minimal pair
    ÃÖ¼Ò ´ë¾î(bet¿Í bed ó·³ °°Àº À§Ä¡ÀÇ ÇÑ °¡Áö ¼Ò¸®¸¸ ´Ù¸¥ ÇÑ ½ÖÀÇ ³¹¸»)
  • effective
    È¿°úÀûÀÎ
  • cost-effective
    ºñ¿ëÈ¿À²ÀûÀÎ
  • effective
    À¯È¿ÇÑ;È¿°úÀûÀÎ;ÀλóÀûÀÎ;»ç½Ç»óÀÇ;½ÇÁ¦ÀÇ;È¿·ÂÀÖ´Â;µ¿¿ø°¡´ÉÇÑ;º´·Â;´«¿¡ ¶ç´Â
  • effective aperture
    (±¤)(·»ÁîÀÇ) À¯È¿ ±¸°æ
  • effective demand
    (°æ)À¯È¿ ¼ö¿ä
  • effective exchange rate
    (±ÝÀ¶)½ÇÈ¿ ȯ½Ã¼¼(ȯÀ²)(±¹Á¦ÅëÈ­±â±ÝÀÌ ´çÇØ±¹°ú ´Ù¸¥ ÁÖ¿ä 20°³±¹ ÅëÈ­ÀÇ È¯½Ã¼¼¸¦ º¹ÇÕ½ÃÄÑ »êÃâÇÏ´Â Áö¼ö)
  • effective money (coin)
    °æÈ­
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á